Genotype and Phenotype in Multiple Sclerosis-Potential for Disease Course Prediction?

Abstract:

PURPOSE OF REVIEW:This review will examine the current evidence that genetic and/or epigenetic variation may influence the multiple sclerosis (MS) clinical course, phenotype, and measures of MS severity including disability progression and relapse rate. RECENT FINDINGS:There is little evidence that MS clinical phenotype is under significant genetic control. There is increasing evidence that there may be genetic determinants of the rate of disability progression. However, studies that can analyse disability progression and take into account all the confounding variables such as treatment, clinical characteristics, and environmental factors are by necessity longitudinal, relatively small, and generally of short duration, and thus do not lend themselves to the assessment of hundreds of thousands of genetic variables obtained from GWAS. Despite this, there is recent evidence to support the association of genetic loci with relapse rate. Recent progress suggests that genetic variations could be associated with disease severity, but not MS clinical phenotype, but these findings are not definitive and await replication. Pooling of study results, application of other genomic techniques including epigenomics, and analysis of biomarkers of progression could functionally validate putative severity markers.

authors

Jokubaitis VG,Zhou Y,Butzkueven H,Taylor BV

doi

10.1007/s11940-018-0505-6

subject

Has Abstract

pub_date

2018-04-24 00:00:00

pages

18

issue

6

eissn

1092-8480

issn

1534-3138

pii

10.1007/s11940-018-0505-6

journal_volume

20

pub_type

杂志文章,评审
  • Arteriovenous Malformations in the Brain.

    abstract::Arteriovenous malformations (AVM) are a leading cause of intracerebral hemorrhage, especially among the young. Because they pose a lifelong risk of serious bleeding, definitive treatment to obliterate the AVM should be pursued in the majority of patients. Microsurgical resection of a small AVM located in the superfici...

    journal_title:Current treatment options in neurology

    pub_type: 杂志文章

    doi:10.1007/s11940-002-0011-7

    authors: Graham GD

    更新日期:2002-11-01 00:00:00

  • Treatment of epilepsy to optimize bone health.

    abstract:OPINION STATEMENT:When treating a person with epilepsy, one must consider many factors in addition to the obvious need to treat the seizures. Both epilepsy itself and treatment with antiepileptic drugs (AEDs) subject one to numerous potential secondary long-term health concerns. Poor bone health is one of these concern...

    journal_title:Current treatment options in neurology

    pub_type: 杂志文章

    doi:10.1007/s11940-011-0133-x

    authors: Pack AM

    更新日期:2011-08-01 00:00:00

  • Depression and quality of life issues in patients with amyotrophic lateral sclerosis.

    abstract::Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease that usually results in death secondary to respiratory failure. The psychological reaction to the diagnosis of ALS in patient and caregiver has received increasing attention. Reports are highly variable as to the severity of depressive symptoms ...

    journal_title:Current treatment options in neurology

    pub_type: 杂志文章

    doi:10.1007/s11940-006-0030-x

    authors: Stromberg SF,Weiss DB

    更新日期:2006-09-01 00:00:00

  • Neurologic Complications of Bone Marrow and Stem-cell Transplantation in Patients with Cancer.

    abstract::Transplantation of bone marrow or peripheral blood stem cells is increasingly being used to treat a variety of oncologic disorders. These procedures are associated with a large spectrum of neurologic complications that significantly contribute to patient morbidity and mortality. These complications may arise at any ti...

    journal_title:Current treatment options in neurology

    pub_type: 杂志文章

    doi:10.1007/s11940-007-0016-3

    authors: Mathew RM,Rosenfeld MR

    更新日期:2007-07-01 00:00:00

  • Immunotherapeutics for autoimmune encephalopathies and dementias.

    abstract:OPINION STATEMENT:The timely implementation of immunotherapy is key to successful treatment of autoimmune encephalopathies or dementias (from here on will be referred to as autoimmune encephalopathies). There are different levels of diagnostic certainty which should guide the immunological treatment of autoimmune encep...

    journal_title:Current treatment options in neurology

    pub_type: 杂志文章

    doi:10.1007/s11940-013-0251-8

    authors: McKeon A

    更新日期:2013-12-01 00:00:00

  • Treatment of sleep disorders in children.

    abstract::Sleep disorders can have a significant impact on the growth and development of children. Behavioral intervention is the first step in the management of many sleep disorders. Limit-setting is particularly challenging in younger children but must be consistent. Good sleep hygiene practices must be emphasized to adolesce...

    journal_title:Current treatment options in neurology

    pub_type: 杂志文章

    doi:10.1007/s11940-007-0042-1

    authors: Lam JC,Mason TB

    更新日期:2007-11-01 00:00:00

  • Subarachnoid Hemorrhage.

    abstract::All patients who present with subarachnoid hemorrhage should be admitted to the intensive care unit for close neurologic and cardiorespiratory monitoring. Neurosurgical consultation should be obtained if external ventricular drain placement, arteriography, or surgical planning are considered. Seizure prophylaxis, anti...

    journal_title:Current treatment options in neurology

    pub_type: 杂志文章

    doi:10.1007/s11940-999-0010-z

    authors: Flemming KD,Brown RD Jr,Wiebers DO

    更新日期:1999-05-01 00:00:00

  • Cerebral vasospasm after aneurysmal subarachnoid hemorrhage and traumatic brain injury.

    abstract:OPINION STATEMENT:Cerebral vasospasm (cVSP) consists of the vasoconstriction of large and small intracranial vessels which can lead to cerebral hypoperfusion, and in extreme cases, delayed ischemic deficits with stroke. While most commonly observed after aneurysmal subarachnoid hemorrhage (aSAH), cVSP can also occur af...

    journal_title:Current treatment options in neurology

    pub_type: 杂志文章

    doi:10.1007/s11940-013-0278-x

    authors: Izzy S,Muehlschlegel S

    更新日期:2014-01-01 00:00:00

  • Primary Central Nervous System Lymphoma.

    abstract::Standard therapy does not exist for the treatment of primary central nervous system lymphoma. This is because of low patient numbers, slow accrual to clinical trials, and the absence of phase III randomized clinical trials. Neuro-oncologists agree that whole brain irradiation alone is no longer the best treatment opti...

    journal_title:Current treatment options in neurology

    pub_type: 杂志文章

    doi:10.1007/s11940-003-0012-1

    authors: Damek DM

    更新日期:2003-05-01 00:00:00

  • Treatment of epilepsy in the elderly.

    abstract::The elderly are the most rapidly growing segment of the population, and the incidence of epilepsy in persons over 65 is higher than in any other age group. In nursing homes, its incidence is even higher than in community-dwelling persons of similar ages. About 10% of nursing home residents are being treated with antie...

    journal_title:Current treatment options in neurology

    pub_type: 杂志文章

    doi:10.1007/s11940-008-0026-9

    authors: Leppik IE

    更新日期:2008-07-01 00:00:00

  • Lysosomal Storage Diseases.

    abstract::Lysosomal storage disorders (LSDs), over 40 different diseases, are now considered treatable disorders. Only a few short years ago, Lysosomal storage disorders were seen as interesting neurodegenerative disorders without any potential for treatment. Effective treatment strategies such as bone marrow transplantation (B...

    journal_title:Current treatment options in neurology

    pub_type: 杂志文章

    doi:10.1007/s11940-001-0006-9

    authors: Kaye EM

    更新日期:2001-05-01 00:00:00

  • Cholesterol lowering to prevent stroke: who, when, and how?

    abstract::The epidemiologic link between increased low-density-lipoprotein (LDL) cholesterol and ischemic stroke is controversial. However, recent trials make it clear that LDL reduction by statin agents in high-risk patients reduces the risk of ischemic stroke. The risk of first stroke is reduced within 1 to 2 years of statin ...

    journal_title:Current treatment options in neurology

    pub_type: 杂志文章

    doi:10.1007/s11940-006-0039-1

    authors: Bernstein RA

    更新日期:2006-11-01 00:00:00

  • Treatment of paroxysmal dyskinesias in children.

    abstract:OPINION STATEMENT:Paroxysmal dyskinesia represents a group of uncommon movement disorders that are characterized by episodes of abnormal movements arising from a baseline of normal or nearly normal movement. Recent advances in the genetics of these disorders have helped provide some unification of classification scheme...

    journal_title:Current treatment options in neurology

    pub_type: 杂志文章

    doi:10.1007/s11940-015-0350-9

    authors: Mink JW

    更新日期:2015-06-01 00:00:00

  • Postintensive Care Syndrome in Pediatric Critical Care Survivors: Therapeutic Options to Improve Outcomes After Acquired Brain Injury.

    abstract:PURPOSE OF REVIEW:Children surviving the pediatric intensive care unit (PICU) with neurologic illness or injury have long-term morbidities in physical, cognitive, emotional, and social functioning termed postintensive care syndrome (PICS). In this article, we review acute and longitudinal management strategies availabl...

    journal_title:Current treatment options in neurology

    pub_type: 杂志文章,评审

    doi:10.1007/s11940-019-0586-x

    authors: Williams CN,Hartman ME,Guilliams KP,Guerriero RM,Piantino JA,Bosworth CC,Leonard SS,Bradbury K,Wagner A,Hall TA

    更新日期:2019-09-27 00:00:00

  • Red Blood Cell Transfusion and Transfusion Alternatives in Traumatic Brain Injury.

    abstract::OPINION STATEMENT: Anemia develops in about 50% of patients hospitalized with traumatic brain injury (TBI) and is recognized as a cause of secondary brain injury. This review examines the effects of anemia and transfusion on TBI patients through a literature search to identify original research on anemia and transfusi...

    journal_title:Current treatment options in neurology

    pub_type: 杂志文章

    doi:10.1007/s11940-012-0167-8

    authors: Kramer AH,Le Roux P

    更新日期:2012-04-01 00:00:00

  • Myoclonus: Pathophysiology and Treatment Options.

    abstract:OPINION STATEMENT:Treatment of myoclonus requires an understanding of the physiopathology of the condition. The first step in treatment is to determine if there is an epileptic component to the myoclonus and treat accordingly. Secondly, a review of medications (e.g., opiates) and comorbidities (e.g., hepatic or renal f...

    journal_title:Current treatment options in neurology

    pub_type: 杂志文章,评审

    doi:10.1007/s11940-016-0404-7

    authors: Levy A,Chen R

    更新日期:2016-05-01 00:00:00

  • Transcranial direct current stimulation for major depression: a general system for quantifying transcranial electrotherapy dosage.

    abstract::There has been a recent resurgence of interest in therapeutic modalities using transcranial weak electrical stimulation through scalp electrodes, such as trans-cranial direct current stimulation (tDCS), as a means of experimentally modifying and studying brain function and possibly treating psychiatric conditions. A r...

    journal_title:Current treatment options in neurology

    pub_type: 杂志文章

    doi:10.1007/s11940-008-0040-y

    authors: Bikson M,Bulow P,Stiller JW,Datta A,Battaglia F,Karnup SV,Postolache TT

    更新日期:2008-09-01 00:00:00

  • Vagus Nerve Stimulation As Treatment for Epileptic Seizures.

    abstract::Vagus nerve stimulation is a unique therapy for epileptic seizures. Two randomized controlled trials in patients with medically refractory partial seizures have demonstrated efficacy, leading to US Food and Drug Administration approval of vagus nerve stimulation therapy in 1997. Extensive safety testing has not reveal...

    journal_title:Current treatment options in neurology

    pub_type: 杂志文章

    doi:10.1007/s11940-003-0002-3

    authors: Salinsky MC

    更新日期:2003-03-01 00:00:00

  • Newly diagnosed high-grade gliomas.

    abstract:OPINION STATEMENT:High-grade or malignant gliomas are aggressive cancers. The World Health Organization (WHO) grading system recognizes grade III and grade IV primary brain tumors of astrocytic, oligodendroglial, or mixed lineage. Identification of these tumors is prompted by symptoms such as insidious headaches, seizu...

    journal_title:Current treatment options in neurology

    pub_type: 杂志文章

    doi:10.1007/s11940-010-0077-6

    authors: Giglio P,Villano JL

    更新日期:2010-07-01 00:00:00

  • Diagnosis and treatment of the neuromuscular manifestations of lyme disease.

    abstract::Although estimates vary, the nervous system appears to be involved in 10% to 15% of patients infected with Borrelia burgdorferi. The resulting disorders, known collectively as neuroborreliosis or nervous system Lyme disease, generally respond well to antimicrobial therapy. Definitive treatment of nervous system infect...

    journal_title:Current treatment options in neurology

    pub_type: 杂志文章

    doi:10.1007/s11940-007-0035-0

    authors: Halperin JJ

    更新日期:2007-03-01 00:00:00

  • Neuralgic amyotrophy.

    abstract::Neuralgic amyotrophy has a broad variety of clinical manifestations. Although it was initially thought to be a plexopathy, its diverse presentation can include isolated sensory nerves or even cranial nerves. Although neuralgic amyotrophy is usually a benign condition with a good recovery, pain can be a disabling featu...

    journal_title:Current treatment options in neurology

    pub_type: 杂志文章

    doi:10.1007/s11940-009-0011-y

    authors: Santana L,Gutierrez A

    更新日期:2009-03-01 00:00:00

  • Treatment of psychosis and dementia in Parkinson's disease.

    abstract:OPINION STATEMENT:Parkinson's disease (PD) has been increasingly recognized as having a multitude of nonmotor symptoms including psychosis, cognitive impairment and dementia, mood disturbances, fatigue, apathy, and sleep disorders. Psychosis and dementia, in particular, greatly affect quality of life for both patients ...

    journal_title:Current treatment options in neurology

    pub_type: 杂志文章

    doi:10.1007/s11940-013-0281-2

    authors: Goldman JG,Holden S

    更新日期:2014-03-01 00:00:00

  • Thrombolysis in the Treatment of Acute Ischemic Stroke.

    abstract::Unfortunately, intravenous alteplase, when administered within 3 hours of symptom onset, remains the only US Food and Drug Administration-approved treatment for acute ischemic stroke; it is now 7 years since its approval. Intra-arterial thrombolysis of middle cerebral and basilar artery occlusions within 6 hours of st...

    journal_title:Current treatment options in neurology

    pub_type: 杂志文章

    doi:10.1007/s11940-003-0028-6

    authors: Haley EC

    更新日期:2003-09-01 00:00:00

  • Usefulness of PET Imaging to Guide Treatment Options in Gliomas.

    abstract:OPINION STATEMENT:Magnetic resonance imaging (MRI) is the gold standard guiding diagnostic and therapeutic management in glioma with its high resolution and possibility to depict blood-brain-barrier disruption when contrast medium is applied. In light of the shifting paradigms revealing distinct tumor subtypes based on...

    journal_title:Current treatment options in neurology

    pub_type: 杂志文章

    doi:10.1007/s11940-015-0384-z

    authors: Suchorska B,Albert NL,Tonn JC

    更新日期:2016-01-01 00:00:00

  • Hemifacial Spasm.

    abstract::Hemifacial spasm (HFS) is a peripheral movement disorder caused by direct or indirect compression or distortion of the root exit zone of the seventh cranial nerve, which is most commonly compressed by an arterial loop, but also may be compressed by a tumor, cyst, or aneurysm. All patients with HFS should undergo magne...

    journal_title:Current treatment options in neurology

    pub_type: 杂志文章

    doi:10.1007/s11940-004-0009-4

    authors: Kemp LW,Reich SG

    更新日期:2004-05-01 00:00:00

  • Treatment of acute migraine in the pediatric population.

    abstract:OPINION STATEMENT:The recognition of the diagnosis of migraine in the pediatric population is increasing. Early and aggressive treatment of migraine in children and adolescents with the use of over-the-counter medications has proven effective. In addition, the off-label use of many migraine-specific medications is ofte...

    journal_title:Current treatment options in neurology

    pub_type: 杂志文章

    doi:10.1007/s11940-010-0069-6

    authors: O'Brien HL,Kabbouche MA,Hershey AD

    更新日期:2010-05-01 00:00:00

  • Subdural Empyema.

    abstract::Subdural empyema represents loculated infection between the outermost layer of the meninges, the dura, and the arachnoid. The empyema may develop intracranially or in the spinal canal. Intracranial subdural empyema is most frequently a complication of sinusitis or, less frequently, otitis or neurosurgical procedures. ...

    journal_title:Current treatment options in neurology

    pub_type: 杂志文章

    doi:10.1007/s11940-003-0019-7

    authors: Greenlee JE

    更新日期:2003-01-01 00:00:00

  • Allodynia as a complication of migraine: background and management.

    abstract::Allodynia is a normal part of the untreated migraine attack in most people with episodic migraine and is prevalent in chronic migraine. The extent to which allo-dynia contributes to the pain and disability of migraine attacks is unclear, as is its clinical importance. The presence of allodynia correlates with the seve...

    journal_title:Current treatment options in neurology

    pub_type: 杂志文章

    doi:10.1007/s11940-009-0001-0

    authors: Young WB

    更新日期:2009-01-01 00:00:00

  • Treatment of nonconvulsive status epilepticus.

    abstract:OPINION STATEMENT:Status epilepticus is a neurologic emergency with significant potential morbidity and even mortality. It should be diagnosed and treated as quickly as possible, with concurrent rapid identification of the underlying cause. Nonconvulsive status epilepticus can be difficult to diagnose due to its protea...

    journal_title:Current treatment options in neurology

    pub_type: 杂志文章

    doi:10.1007/s11940-012-0179-4

    authors: Pang T,Drislane FW

    更新日期:2012-08-01 00:00:00

  • Triptans: where things stand.

    abstract:OPINION STATEMENT:Triptans, selective serotonin receptor agonists, were developed almost 20 years ago and represented a major breakthrough in the treatment of acute migraine attacks. Since then, the triptans have become first-line agents for most patients with migraine, both with and without aura, unless contraindicate...

    journal_title:Current treatment options in neurology

    pub_type: 杂志文章

    doi:10.1007/s11940-010-0082-9

    authors: Cole AK,Marmura MJ

    更新日期:2010-09-01 00:00:00